Home > Node

Innovation Blossoms

The three Sopharma AD factories - the one in Kazanlak, the Tablet production and Ampoule production in Sofia - have Nivalin in common, one of the strongest Sopharma products. Nivalin is sold in more than 10 countries outside Bulgaria, making it one of the most famous Sopharma products.  It increases the intensity of the reflex centers of the spinal cord, medulla oblongata and cerebral cortex, thus influences all links of the reflex arc.

English

Sales revenues for September 2024

Sofia, Bulgaria October 21, 2024 – According to the requirements of Art. 100t of the Law on Public Offering of Securities (LPOS), “Sopharma” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies, that for September 2024 the Company recorded a decrease in sales of 16% compared to the same month of the previous year, incl. 15% decrease in domestic sales and 16% decrease in export sales.

For the period from the beginning of 2024, the Company recorded a decrease in sales of 8%, incl. 5% increase of domestic sales and 15% decrease in export sales.

English

Notification according to Art. 89t of the LPOS concerning an increase of the capital of "SOPHARMA" AD, by exercising warrants from the issue with ISIN BG9200001212

Sofia, Bulgaria October 14, 2024 - According to the requirements of Art. 89t of the LPOS, "Sopharma" AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies all interested parties that the Company on the basis of Art. 89t of the Law on the Public Offering of Securities, in connection with the decision of the Board of Directors of "SOPHARMA" AD dated October 14, 2024 and on the basis of Art. 195 and 196 of the Commercial Law (CL), Art. 113, para. 2, it. 2 of the LPOS and Art.

English

Notification for initiation of acquisition transaction

Sofia, Bulgaria, October 4, 2024 – According to the requirements of art. 100t of the Law on Public Offering of Securities (LPOS), “Sopharma” AD (the Company, SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies, that following its growth strategy and its goal of becoming a stronger regional player, the Company initiates a transaction for acquisition of a pharmaceutical product portfolio consisting of both CHC and prescription products in the following therapeutic areas: Sex hormones and modulators of the genital system, Urologicals and Antivirals for systemic use.

English

Pages